AQST — Aquestive Therapeutics, Inc.

Is AQST overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of August 19, 2026

Aquestive Therapeutics, Inc. (AQST) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $4.32. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

Aquestive Therapeutics, Inc. (AQST) is a small-cap specialty drug-delivery company with differentiated platform technologies that provide multiple commercialization and partnering pathways. The company benefits from durable secular demand for alternative delivery formats and potential CDMO/biologics tailwinds, but financial and execution risks are material: limited scale, potential negative cash flow, and dependence on regulatory and reimbursement outcomes raise uncertainty. Near-term upside would be driven by successful product commercialization, favorable payer decisions, partnership deals, or positive regulatory milestones; downside scenarios include failed trials, manufacturing setbacks, or the need for dilutive financing. Market sentiment is currently cautiously optimistic for growth names, which could support short-term share appreciation if operational news is constructive.

Key factors

  • Aquestive Therapeutics, Inc. (AQST) operates proprietary drug delivery platforms (oral thin film, transdermal and other non-oral formulations) that provide differentiation versus traditional dosage forms and create licensing/commercial partnership opportunities
  • Niche commercial products and any recent incremental revenue streams reduce binary clinical-only risk versus pure R&D-stage biotech
  • Sector thematic tailwinds for biologics/CDMO demand and expanded access policies that can increase demand for differentiated delivery formats and commercial channels
  • Partnering and licensing optionality can accelerate commercialization and de-risk development spending while providing non-dilutive revenue
  • Recent mild risk-on market tone toward growth names supports short-term valuation re-ratings for small-cap biopharma with visible catalysts
  • Market perception is mixed but improves with successful execution on commercial rollouts, supply scale-up and payer coverage

Risks

  • Clinical and regulatory risk for pipeline assets or label expansions; adverse trial or regulator outcomes would materially affect valuation
  • Commercial execution risk: limited sales infrastructure could hamper uptake and reimbursement negotiations may be slow or unfavorable
  • Manufacturing and scale-up risk for platform technologies, including quality, capacity and cost challenges
  • Funding and dilution risk: small-cap biopharma often require additional equity or partnership funding if cash runway is limited
  • Competitive risk from alternative delivery technologies and incumbents developing similar formulations or new therapeutic alternatives
  • Broader market volatility and sector rotation could compress multiples and lead to share-price weakness despite fundamental progress

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AQST — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.